Cancers Treated:
Specializing In:
- Brain metastases of breast cancer
- Metastatic breast cancer
Research Interests:
- Quiescent cancer cells
- Drug resistance
- Metastatic breast cancer
- Dormancy
- Biomarkers
Positions
Roswell Park Comprehensive Cancer Center
- Associate Professor of Oncology
- Chief of Breast Medicine – Department of Medicine
- Director of Breast Translational Research
- Department of Molecular and Cellular Biology
Background
Education and Training
- 2009 - BMBCH - Oxford University Medical School, Oxford, England
- 2006 - MA - University of Cambridge, Cambridge, England
- 2004 - BS - Yale College, New Haven, CT
Residency
- 2010-2013 - Mass General Hospital, Boston, MA
Fellowship
- 2013-2017 - Dana-Farber Cancer Institute and Mass General Brigham, Boston, MA
Board Certification
- Internal Medicine - American Board of Internal Medicine
- Medical Oncology - American Board of Medical Specialties
Professional Memberships
- AACR
- ASCO
- American Society of Cell Biology
Research Overview
Clinical Trials
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Learn More
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Learn More
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Learn More
Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
Learn More
